---
title: "300813.SZ (300813.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300813.SZ/news.md"
symbol: "300813.SZ"
name: "300813.SZ"
parent: "https://longbridge.com/en/quote/300813.SZ.md"
datetime: "2026-05-21T21:44:41.982Z"
locales:
  - [en](https://longbridge.com/en/quote/300813.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300813.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300813.SZ/news.md)
---

# 300813.SZ (300813.SZ) — Related News

### [TAILIN BIOTECH: The company currently does not have any testing reagent products among its products](https://longbridge.com/en/news/286730547.md)
*2026-05-18T07:29:27.000Z*
> On May 18th, in response to investors' question about "Can the company detect hantavirus?", TAILIN BIOTECH replied on th

### [TAILIN BIOTECH: Wholly-owned subsidiary recently obtained 5 patent certificates](https://longbridge.com/en/news/285900122.md)
*2026-05-11T07:43:32.000Z*
> TAILIN BIOTECH announced that its wholly-owned subsidiaries, Tailin Medical Engineering, Tailin Life Sciences, and Taili

### [TAILIN BIOTECH released its first-quarter performance, with a net profit attributable to the parent company of 4.8403 million yuan, an increase of 37.19%](https://longbridge.com/en/news/284519444.md)
*2026-04-29T08:09:04.000Z*
> TAILIN BIOTECH released its Q1 2026 performance, with operating revenue of 70.0635 million yuan, a year-on-year increase

### [TAILIN BIOTECH: Completed the repurchase of 1% of the company's total shares](https://longbridge.com/en/news/283958952.md)
*2026-04-24T08:20:25.000Z*
> TAILIN BIOTECH announced that as of April 22, 2026, the company has repurchased a total of 1.218 million shares through 

### [TAILIN BIOTECH: Obtained 3 trademarks, 1 patent, and 1 software copyright](https://longbridge.com/en/news/282973089.md)
*2026-04-16T09:33:53.000Z*
> TAILIN BIOTECH announced that the company and its wholly-owned subsidiaries, Tailin Life Sciences and Tailin Medical Eng

### [TAILIN BIOTECH: Plans to issue convertible corporate bonds with a total amount not exceeding 230 million yuan](https://longbridge.com/en/news/280614639.md)
*2026-03-26T10:52:40.000Z*
> TAILIN BIOTECH announced that it plans to issue convertible corporate bonds with a total amount not exceeding 230 millio

### [TAILIN BIOTECH released its 2025 annual performance, with a net profit attributable to the parent company of 16.4854 million yuan, an increase of 26.32%](https://longbridge.com/en/news/280598267.md)
*2026-03-26T09:11:28.000Z*
> TAILIN BIOTECH released its annual report for 2025, with operating revenue of 340 million yuan, a year-on-year decrease 

### [TAILIN BIOTECH: Plans to distribute 0.3 yuan for every 10 shares in the fiscal year 2025, with a cumulative dividend payout ratio of nearly 96%](https://longbridge.com/en/news/280595170.md)
*2026-03-26T08:52:54.000Z*
> TAILIN BIOTECH announced plans to hold a meeting on March 25, 2026, to review the profit distribution plan for the year 

### [TAILIN BIOTECH: Subsidiary recently obtained 2 patent certificates](https://longbridge.com/en/news/278350169.md)
*2026-03-09T07:50:53.000Z*
> TAILIN BIOTECH announced that its wholly-owned subsidiary recently obtained 2 patent certificates, including 1 invention